Half of Patients With Newly Diagnosed Vitiligo Do Not Receive Treatment
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 17, 2023 -- A high proportion of patients with newly diagnosed vitiligo do not receive any treatment, according to a study recently published in Dermatology and Therapy.
David Rosmarin, M.D., from the Indiana University School of Medicine in Indianapolis, and colleagues retrospectively analyzed claims data from the Merative MarketScan Research Databases. The analysis included data from 19,335 patients aged 12 years and older with newly diagnosed vitiligo.
The researchers found that 49.9 percent of patients did not receive any treatment in the 12-month follow-up. Among those initiating treatment, switching was minimal, with the most frequent first-line treatments being high-potency topical corticosteroids (25.4 percent), oral corticosteroids (23.1 percent), and topical calcineurin inhibitors (TCIs; 14.7percent). Among adolescents initiating treatment, TCI was the most frequently received first-line therapy (30.9 percent). During follow-up, patients with moderate-to-severe vitiligo were very likely to receive treatment, with only 1.5 percent not receiving treatment. Time to first medication claim ranged from 51.9 days for TCI to 178.6 days for systemic immunosuppressants. The mean total days supplied ranged from 14.4 days for oral corticosteroids to 121.0 for immunosuppressants.
"To help better understand the needs of patients with vitiligo, future studies need to examine which demographic and clinical characteristics are associated with not receiving treatments for vitiligo," the authors write.
Rosmarin disclosed ties to pharmaceutical companies, including AbbVie, which funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Mortality in Rheumatic Heart Disease Is High
FRIDAY, June 7, 2024 -- Mortality related to rheumatic heart disease (RHD) is high and is correlated with the severity of valve disease, according to a study published online June...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
Metabolic Impact on Offspring Similar for Frozen, Fresh Embryo Transfer
FRIDAY, June 7, 2024 -- For glucose and lipid profiles during early childhood, the impact of frozen embryo transfer (FET) is comparable to that of fresh embryo transfer, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.